Harmony Biosciences Holdings Inc. (HRMY): Price and Financial Metrics

Harmony Biosciences Holdings Inc. (HRMY): $41.33

2.20 (+5.62%)

POWR Rating

Component Grades













Add HRMY to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where HRMY ranks best; there it ranks ahead of 92.59% of US stocks.
  • The strongest trend for HRMY is in Value, which has been heading down over the past 179 days.
  • HRMY ranks lowest in Momentum; there it ranks in the 12th percentile.

HRMY Stock Summary

  • Harmony Biosciences Holdings Inc's stock had its IPO on August 19, 2020, making it an older stock than merely 3.38% of US equities in our set.
  • With a price/earnings ratio of 85.41, Harmony Biosciences Holdings Inc P/E ratio is greater than that of about 91.9% of stocks in our set with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, Harmony Biosciences Holdings Inc is reporting a growth rate of -803.78%; that's higher than merely 2.65% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Harmony Biosciences Holdings Inc are OSIS, PRTK, NCR, QUOT, and ESTA.
  • HRMY's SEC filings can be seen here. And to visit Harmony Biosciences Holdings Inc's official web site, go to www.harmonybiosciences.com.

HRMY Valuation Summary

  • HRMY's EV/EBIT ratio is 36.1; this is 23.21% higher than that of the median Healthcare stock.
  • Over the past 13 months, HRMY's price/sales ratio has gone down 380.6.
  • HRMY's price/sales ratio has moved down 380.6 over the prior 13 months.

Below are key valuation metrics over time for HRMY.

Stock Date P/S P/B P/E EV/EBIT
HRMY 2021-08-31 8.2 15.3 112.4 36.1
HRMY 2021-08-30 9.0 16.7 122.9 39.5
HRMY 2021-08-27 8.5 15.9 117.0 37.6
HRMY 2021-08-26 8.3 15.5 114.1 36.7
HRMY 2021-08-25 8.4 15.6 115.1 37.0
HRMY 2021-08-24 8.0 14.9 109.9 35.4

HRMY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HRMY has a Quality Grade of B, ranking ahead of 93.01% of graded US stocks.
  • HRMY's asset turnover comes in at 0.652 -- ranking 49th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows HRMY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.652 0.826 0.314
2020-12-31 0.599 0.826 -0.095

HRMY Price Target

For more insight on analysts targets of HRMY, see our HRMY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.33 Average Broker Recommendation 1.38 (Strong Buy)

HRMY Stock Price Chart Interactive Chart >

Price chart for HRMY

HRMY Price/Volume Stats

Current price $41.33 52-week high $54.00
Prev. close $39.13 52-week low $25.09
Day low $39.51 Volume 348,400
Day high $41.53 Avg. volume 467,032
50-day MA $45.69 Dividend yield N/A
200-day MA $39.98 Market Cap 2.44B

Harmony Biosciences Holdings Inc. (HRMY) Company Bio

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

HRMY Latest News Stream

Event/Time News Detail
Loading, please wait...

HRMY Latest Social Stream

Loading social stream, please wait...

View Full HRMY Social Stream

Latest HRMY News From Around the Web

Below are the latest news stories about Harmony Biosciences Holdings Inc that investors may wish to consider to help them evaluate HRMY as an investment opportunity.

Berkeley Lights, Inc. (BLI) Reports Q4 Loss, Tops Revenue Estimates

Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -4% and 5.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

3 Desirable Drug Stocks With Very Promising Pipelines

Drug makers with superb pipelines are likely to deliver great returns for long-term investors.

Larry Ramer on InvestorPlace | February 16, 2022

Read This Before Judging Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) ROE

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Yahoo | February 16, 2022

Harmony Biosciences Announces Date of Fourth Quarter and Full Year 2021 Financial Results

Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's fourth quarter and full year 2021 financial results on Monday, February 28, 2022. Following the release, Harmony will conduct a conference call and live webcast on the same day, at 8:30 a.m. ET.

Yahoo | February 14, 2022

When To Sell A Stock: This IBD 50 Pharma Stock Plummeted — Here's How To Avoid Major Losses

On Jan. 5, Harmony shares triggered an important sell rule upon entering the 7%-8% sell zone.

Yahoo | January 24, 2022

Read More 'HRMY' Stories Here

HRMY Price Returns

1-mo -18.74%
3-mo 7.57%
6-mo 11.82%
1-year 28.71%
3-year N/A
5-year N/A
YTD -3.07%
2021 17.95%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6569 seconds.